David Elsley
Fondatore presso CARDIOL THERAPEUTICS INC.
Patrimonio netto: 2 M $ in data 30/06/2024
Profilo
David G.
Elsley is the founder.
He founded Vasogen, Inc. in 1990 and held the title of Director until 2009.
He also founded Cardiol Therapeutics, Inc. in 2017 and currently holds the titles of President, Chief Executive Officer & Director.
Mr. Elsley has an MBA from the University of Western Ontario and the Richard Ivey School of Business.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 24/06/2024 | 1 204 500 ( 1.75% ) | 2 M $ | 30/06/2024 |
Posizioni attive di David Elsley
| Società | Posizione | Inizio |
|---|---|---|
| CARDIOL THERAPEUTICS INC. | Fondatore | 19/01/2017 |
Precedenti posizioni note di David Elsley
| Società | Posizione | Fine |
|---|---|---|
Vasogen, Inc.
 Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Fondatore | 23/10/2009 |
Formazione di David Elsley
| Richard Ivey School of Business | Masters Business Admin |
| University of Western Ontario | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| CARDIOL THERAPEUTICS INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Health Technology |
- Borsa valori
- Insiders
- David Elsley
